TY - JOUR
T1 - Lyman–Kutcher–Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy
T2 - LKB NTCP modeling for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy
AU - Wang, Zeming
AU - Chen, Mei
AU - Sun, Jian
AU - Jiang, Shengpeng
AU - Wang, Li
AU - Wang, Xiaochun
AU - Sahoo, Narayan
AU - Gunn, G. Brandon
AU - Frank, Steven J.
AU - Nguyen, Quynh Nhu
AU - Liao, Zhongxing
AU - Chang, Joe Y.
AU - Zhu, X. Ronald
AU - Zhang, Xiaodong
N1 - Funding Information:
The University of Texas MD Anderson Cancer Center was supported in part by the National Cancer Institute Cancer Center Support Grant P30CA016672 . We would like to thank Sarah Bronson in Scientific Publications, Research Medical Library at The University of Texas MD Anderson Cancer Center for the editing assistance.
Funding Information:
The University of Texas MD Anderson Cancer Center was supported in part by the National Cancer Institute Cancer Center Support Grant P30CA016672. We would like to thank Sarah Bronson in Scientific Publications, Research Medical Library at The University of Texas MD Anderson Cancer Center for the editing assistance.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/5
Y1 - 2020/5
N2 - Purpose: To develop and test an Lyman–Kutcher–Burman (LKB) normal tissue complication probability (NTCP) model to predict radiation-induced esophagitis (RE) in non-small cell lung cancer (NSCLC) patients receiving passive-scattering proton therapy (PSPT). Material and methods: We retrospectively reviewed 328 NSCLC patients receiving PSPT at our institution. Esophagitis severity was graded by physicians according to the Common Toxicity Criteria for Adverse Events version 3.0, and the primary endpoint was grade ≥2 RE within 6 months from the first treatment. LKB model parameters (n, m, and TD50) were determined using maximum likelihood estimation. Overall performance of the model was quantified by Nagelkerke's R2 and the scaled Brier score. Discriminative ability was evaluated using the area under the receiver operating curve (AUC), and calibration was assessed with the Hosmer–Lemeshow goodness-of-fit test. Bootstrap internal validation was performed to assess the model uncertainty and generalizability. Results: Grade 2–3 RE was observed in 136 (41.5%) patients, and no grade 4–5 RE was reported. The optimal LKB parameters were: n = 0.24, m = 0.51, and TD50 = 44.83 Gy (relative biological effectiveness). The optimism-corrected AUC was 0.783, and the Hosmer–Lemeshow test showed significant agreement between predicted and observed morbidity. Bootstrap validation verified that the model was robust to similar future populations. Conclusion: Our LKB NTCP model to predict grade ≥2 RE in NSCLC patients who received PSPT showed good predictive performance and robustness to similar future populations, and a smaller volume effect than the previously observed in photon-treated populations. External validation of the model is warranted.
AB - Purpose: To develop and test an Lyman–Kutcher–Burman (LKB) normal tissue complication probability (NTCP) model to predict radiation-induced esophagitis (RE) in non-small cell lung cancer (NSCLC) patients receiving passive-scattering proton therapy (PSPT). Material and methods: We retrospectively reviewed 328 NSCLC patients receiving PSPT at our institution. Esophagitis severity was graded by physicians according to the Common Toxicity Criteria for Adverse Events version 3.0, and the primary endpoint was grade ≥2 RE within 6 months from the first treatment. LKB model parameters (n, m, and TD50) were determined using maximum likelihood estimation. Overall performance of the model was quantified by Nagelkerke's R2 and the scaled Brier score. Discriminative ability was evaluated using the area under the receiver operating curve (AUC), and calibration was assessed with the Hosmer–Lemeshow goodness-of-fit test. Bootstrap internal validation was performed to assess the model uncertainty and generalizability. Results: Grade 2–3 RE was observed in 136 (41.5%) patients, and no grade 4–5 RE was reported. The optimal LKB parameters were: n = 0.24, m = 0.51, and TD50 = 44.83 Gy (relative biological effectiveness). The optimism-corrected AUC was 0.783, and the Hosmer–Lemeshow test showed significant agreement between predicted and observed morbidity. Bootstrap validation verified that the model was robust to similar future populations. Conclusion: Our LKB NTCP model to predict grade ≥2 RE in NSCLC patients who received PSPT showed good predictive performance and robustness to similar future populations, and a smaller volume effect than the previously observed in photon-treated populations. External validation of the model is warranted.
KW - Lyman–Kutcher–Burman model
KW - Non–small cell lung cancer
KW - Normal tissue complication probability
KW - Passive-scattering proton therapy
KW - Radiation-induced esophagitis
UR - http://www.scopus.com/inward/record.url?scp=85082191628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082191628&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2020.03.003
DO - 10.1016/j.radonc.2020.03.003
M3 - Article
C2 - 32220701
AN - SCOPUS:85082191628
SN - 0167-8140
VL - 146
SP - 200
EP - 204
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -